66357-35-5

• 常用中文名：雷尼替丁
• 常用英文名：Ratic
• CAS号：66357-35-5
• 分子式：C₁₃H₂₂N₄O₃S
• 分子量：314.404
• 相关类别： 原料药 消化系统用药 抑制胃酸分泌药
• 发布时间：2018-02-08 08:00:00
• 更新时间：2026-07-02 16:30:16
• 【用途一】
  消化系统用药，用于缓解胃酸过多所致的胃痛、胃灼热、返酸等
  【用途二】
  强效、长效组胺H2受体拮抗剂。能有效地抑制基础胃酸及胃泌素刺激引起的胃酸分泌，降低胃酸和胃酶的活性。作用比西咪替丁强5～8倍，且维持时间长，而且无西咪替丁对中枢神经系统、性腺等的不良反应。用于胃及十二指肠溃疡及胃酸高分泌疾病、反流性食道炎。
  【用途三】
  长效强效的H2受体拮抗剂，有效地抑制组胺、五肽胃泌素及食物刺激引起的胃酸分泌，降低基本规律础胃酸，抑制胃酶的活性。其作用强度为西咪替丁的5-8倍。本品适用于良性胃及十二脂肠溃疡、术后溃疡、反流性食管炎及卓-艾氏综合症等。

名称

• 中文名: 雷尼替丁
• 英文名: ranitidine
• 中文别名: 甲硝呋; 善胃得; 胃安太; 雷尼替丁检测标准品; 雷尼替丁建; 雷尼替丁-D6; N' (-甲基-N-[2-[[[5-[(二甲氨基)甲基-2-呋喃基]甲基]硫代]乙基]-2-硝基-1,1-乙烯二胺; 雷尼替丁溶液, 100PPM; 雷尼替丁(呋喃硝胺); 甲醇中雷尼替丁溶液; 雷尼替丁碱; 雷尼替丁,10 MM DMSO 溶液; 呋喃硝胺; 盐酸雷尼替丁; N-[2-[[[5-[(二甲基氨基)甲基]-2-呋喃基]甲基]硫代]乙基]-N'-甲基-2-硝基-1,1-乙烯二胺; 呋硫硝胺; 甲硝呋胍; N'-甲基-N-[2-[[[5-[(二甲氨基)甲基]-2-呋喃基]-甲基]硫代]乙基]-2-硝基-1,1-乙烯二胺盐酸盐; 胃安太定; 善得胃
• 英文别名: Ranitidine hydrochlo; Ranitidin; (E)-N-(2-(((5-((diMethylaMino)Methyl)furan-2-yl)Methyl)thio)ethyl)-N-Methyl-2-nitroethene-1,1-diaMine; Sostril; RANITIDINE HYDROCHLORIDE IH; Terposen; RanitidineQ: What is Ranitidine Q: What is the CAS Number of Ranitidine Q: What is the storage condition of Ranitidine Q: What e the applications of Ranitidine; Ranitidine (Rantadine) HCl; yl)-n-methyl-2-nitro; 1,1-ethenediamine,n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethy; MFCD00081180; N-[2-[[5-[(Dimethylamino)methyl]furfuryl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine; 1-(Methylamino)-1-[[2-[[5-(dimethylaminomethyl)-2-furyl]methylthio]ethyl]amino]-2-nitroethene; N’-Methyl-N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-2-nitro-1-ethenedinine; Trigger; U1tidine; N-[1-(Methylamino)-2-nitroethenyl]-2-[5-(dimethylaminomethyl)furan-2-ylmethylthio]ethanamine; Raticina; Ranitidine hydrochloride HCL form II; n-(2-(((-5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n’-methyl-2-ni; RANITIDINE USP; U1cex; (E)-N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine; {2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}[(E)-1-(methylamino)-2-nitroethenyl]amine; N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethanediaminehydrochloride; Ranitidine Reference Standd; N'-[2-[[5-(Dimethylaminomethyl)-2-furyl]methylsulfanyl]ethyl]-N-methyl-2-nitro-ethene-1,1-diamine hydrochloride; 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro; RANITIDINE BASE; Ranitidine - Bio-X; Ranitidine hydrochloride COS; l)-n’-methyl-2-nitro; Zantae; Taural; Ranitidine, 10 mM in DMSO; RANITIDINE FORM I; Samp; TIMTEC-BB SBB006527; tro-1,1-ethenediamine; Ranitidine; Zantic; 1,1-ethenediamine,n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)eth; RANITIDINE FORM II; EINECS 266-332-5; RANITIDINE; N-[2-[[5-[(Dimethylamino)methyl]furfuryl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethylenediamine

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 437.1±45.0 °C at 760 mmHg
• 熔点: 69-70°C
• 分子式: C₁₃H₂₂N₄O₃S
• 分子量: 314.404
• 闪点: 218.2±28.7 °C
• 精确质量: 314.141266
• PSA: 111.56000
• LogP: 1.23
• 外观性状: 白色粉末
• 蒸汽压: 0.0±1.0 mmHg at 25°C
• 折射率: 1.559
• 储存条件: Desiccate at +4°C
• 水溶解性: 24.7 mg/mL
• 分子结构:

  1、 摩尔折射率：85.64

  2、 摩尔体积（cm³/mol）：265.4

  3、 等张比容（90.2K）：687.5

  4、 表面张力（dyne/cm）：45.0

  5、 极化率（10-24cm3）：33.95

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:2

  3.氢键受体数量:7

  4.可旋转化学键数量:9

  5.互变异构体数量:2

  6.拓扑分子极性表面积112

  7.重原子数量:21

  8.表面电荷:0

  9.复杂度:347

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:1

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1.性状：类白色或淡黄色结晶性粉末，有异臭，味微苦且涩

  2.熔点（ºC）：137~143。

  3.溶解性：易溶于甲醇或水或乙酸，微溶于乙醇，几乎不溶于氯仿或丙酮。

生物活性

• 描述: Ranitidine 是一种有效的,选择性的,具有口服活性的组胺 H2 受体 (histamine H2-receptor) 拮抗剂,IC50 为 3.3 μM,可抑制胃液分泌。Ranitidine 还一种是 CYP2C19 和 CYP2C9 的弱抑制剂。
• 相关类别:
  信号通路 >> 免疫及炎症 >> 组胺受体
  研究领域 >> 内分泌
  研究领域 >> 感染
  信号通路 >> 代谢酶/蛋白酶 >> 细胞色素P450
  研究领域 >> 代谢疾病
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 组胺受体
  信号通路 >> 抗感染 >> 细菌
• 靶点:

  H2 Receptor:3.3 μM (IC50)

  CYP2C19

  CYP2C9

• 参考文献:

  [1]. A W Herling, et al. Inhibition of 14C-aminopyrine accumulation in isolated rabbit gastric glands by the H2-receptor antagonist HOE 760 (TZU-0460). Agents Actions. 1987 Feb;20(1-2):35-9.

  [2]. A Leucuta, et al. A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. Drug Metabol Drug Interact. 2004;20(4):273-81.

  [3]. Antonio Francesco Ciccaglione, et al. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter. 2019 Oct;24(5):e12606.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : KM6556500 CHEMICAL NAME : 1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)th io)ethyl)-N'-methyl- 2-nitro- CAS REGISTRY NUMBER : 66357-35-5 LAST UPDATED : 199703 DATA ITEMS CITED : 7 MOLECULAR FORMULA : C13-H22-N4-O3-S MOLECULAR WEIGHT : 314.45 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 12 mg/kg/2D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - interstitial nephritis Blood - other changes Skin and Appendages - dermatitis, allergic (after topical exposure) REFERENCE : AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 12,67,1994 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 93 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2018 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 884 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 25,749,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 80 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 280 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602

安全

• 安全声明 (欧洲): S22-S24/25
• WGK德国: 2
• RTECS号: KM6557000
• 海关编码: 2932999099

上下游产品

上游产品  5
66356-53-4 7440-44-0 13623-94-4 66357-07-1
75-52-5
下游产品  5
66357-59-3 15433-79-1 112233-24-6 112233-23-5
112233-25-7

制备

【方法一】
5-[(二甲氨基)甲基]-2-呋喃甲醇(I)和半胱氨酸反应，生成2-[[5-[(二甲氨基)甲基-2-呋喃基]甲基]硫代]乙胺(Ⅱ)。
230g N-甲基-1-甲硫基-2-硝基乙烯甲胺溶于400ml水，45～50℃加热搅拌，在4h内滴加321g化合物(Ⅱ)，加完后继续搅拌3.5h。然后再回流0.5h，冷却到。70℃，加入2L 4-甲基-2-戊酮。在减压(34.7kPa)下共沸蒸出水，然后在50℃下和10g活性炭作用。过滤除去活性炭后，冷至10℃，过滤析出的雷尼替丁，干燥，约得380g，熔点69～70℃。

海关

海关编码	2932999099
中文概述	2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%